Biography

Dr. Kochenderfer is a clinician and translational researcher in the Experimental Transplantation and Immunology Branch of the National Cancer Institute (NCI). Dr. Kochenderfer conducts research aimed at developing new T-cell therapies for lymphoma and leukemia. His clinical expertise lies in the areas of hematopoietic stem cell transplantation and hematologic malignancies. Dr. Kochenderfer received his M.D. from West Virginia University in 1995, and he completed clinical training in internal medicine at Vanderbilt University. He completed oncology and hematology fellowships at the University of Texas M.D. Anderson Cancer Center and at Baylor College of Medicine. He completed further training in tumor immunology and stem cell transplantation at the NCI prior to assuming his current position as an Assistant Clinical Investigator. 

Research Intrest

Clinical Research, Immunology 

List of Publications
Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, et al. (2013) B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19: 2048-60.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 33: 540-9.
Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, et al (2016) Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J Clin Oncol. 34: 1112-21.
Ali SA, Shi V, Maric I, Wang M, Stroncek DF, et al. (2016) T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 128 1688-1700
Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, et al. (2017) Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 35: 1803-1813.